Fig. 4: Knockout of AR by CRISPR/Cas9 is not sufficient to provide radiosensitisation to AR+/ER+ cells alone or in combination with ER inhibitors. | British Journal of Cancer

Fig. 4: Knockout of AR by CRISPR/Cas9 is not sufficient to provide radiosensitisation to AR+/ER+ cells alone or in combination with ER inhibitors.

From: Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer

Fig. 4

CRISPR/Cas9-mediated knockout of AR was confirmed by western blot a in CAMA-1 and ZR-75-1 cells. b Radiosensitisation of CAMA-1 AR KO or Cas9 control cells was assessed by clonogenic survival assay alone or in combination with tamoxifen or fulvestrant treatment. Radiosensitisation of ZR-75-1 c Cas9 control cells or d AR KO cells with tamoxifen was assessed by clonogenic survival assay. Similarly, radiosensitisation with fulvestrant was assessed in ZR-75-1 e Cas9 control or f AR KO cells. Representative clonogenic survival assays are shown for each cell line, and the SF-2Gy are representative of three independent experiments (mean ± SEM). *p < 0.05, **p < 0.01; NS not significant.

Back to article page